Career
BioInvent, based in Lund, Sweden, employs around 60 people and fosters a collaborative team environment.
bioinvent.comCrawled Nov 20, 2026
BioInvent, based in Lund, Sweden, employs around 60 people and fosters a collaborative team environment.
Transgene S.A. reports ongoing advancements in clinical trials and provides a financial update for the third quarter of 2026. The company highlights progress in its pipeline of therapeutic candidates, though specific details on trials or results remain undisclosed. Investors await further disclosures on performance and pipeline developments.
Transgene and BioInvent initiate a Phase 1 clinical trial testing **BT-001**, an experimental therapy, in patients with **rectal cancer**. The first participant receives the treatment as part of the study evaluating safety and efficacy. BT-001 combines technologies from both companies to target cancer cells.
Zelluna ASA releases its third-quarter 2026 financial performance, detailing revenue, operational updates, and strategic progress. The company highlights advancements in its core business segments, though specific figures remain undisclosed in the preliminary announcement. Investors await further details on profitability and growth initiatives.
BioInvent reports positive clinical data in early 2025, advancing its first-in-class immunomodulatory antibodies for cancer treatment. The company’s pipeline targets novel mechanisms to enhance immune responses against tumors. This progress supports ongoing efforts to develop next-generation therapies in oncology.
Exelixis secures exclusive rights to develop antibody-based immuno-oncology therapies using BioInvent’s proprietary screening platform and antibody library. The agreement allows Exelixis to select and advance novel antibody candidates targeting specific immuno-oncology pathways. This partnership expands Exelixis’s biotherapeutics pipeline with potential new treatment options for cancer patients.